Due to incorrect information from the companies, the story previously stated the number of targets per reaction that can be detected by Seegene's assay chemistries was seven. The error has been corrected.
NEW YORK – Bio-Rad Laboratories will partner with Seegene to develop and commercialize multiplex molecular diagnostic tests for infectious diseases, the firm announced on Wednesday.
Seoul, South Korea-based Seegene will provide multiplex assays for Bio-Rad's CFX96 Dx Real-Time PCR System under the terms of the agreement. The tests will be for the US market after clinical development and clearance from the US Food and Drug Administration.
Seegene's assay chemistries can detect as many as 10 targets per reaction and provide results in approximately four hours, Bio-Rad said in a statement.
"Seegene's unique assay design, chemistries, and high-level multiplexing can detect multiple infectious disease targets simultaneously, making the assays well suited for syndromic testing," said Dara Wright, Bio-Rad's executive VP and president of clinical diagnostics.
Financial terms of the partnership were not disclosed.